Allergan plc (NYSE:AGN) – Stock analysts at SunTrust Banks upped their Q3 2018 earnings per share estimates for shares of Allergan in a research note issued on Wednesday, October 17th. SunTrust Banks analyst J. Boris now forecasts that the company will post earnings of $4.28 per share for the quarter, up from their previous estimate of $4.13. SunTrust Banks has a “Buy” rating and a $218.00 price objective on the stock. SunTrust Banks also issued estimates for Allergan’s FY2018 earnings at $16.54 EPS and FY2020 earnings at $19.14 EPS.

A number of other equities research analysts also recently issued reports on the stock. Wells Fargo & Co reissued a “buy” rating on shares of Allergan in a research note on Wednesday. Cowen set a $255.00 price target on shares of Allergan and gave the company a “buy” rating in a research note on Wednesday. Guggenheim assumed coverage on shares of Allergan in a research note on Monday, October 8th. They issued a “buy” rating on the stock. Zacks Investment Research downgraded shares of Allergan from a “hold” rating to a “sell” rating in a research note on Wednesday, October 3rd. Finally, ValuEngine raised shares of Allergan from a “strong sell” rating to a “sell” rating in a research note on Friday, September 21st. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $211.91.

Allergan stock opened at $189.53 on Friday. The company has a market capitalization of $64.12 billion, a PE ratio of 11.59, a P/E/G ratio of 1.45 and a beta of 1.19. Allergan has a 1 year low of $142.81 and a 1 year high of $197.00. The company has a current ratio of 1.00, a quick ratio of 0.85 and a debt-to-equity ratio of 0.34.

Allergan (NYSE:AGN) last posted its earnings results on Thursday, July 26th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.13 by $0.29. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $3.92 billion. Allergan had a negative net margin of 10.29% and a positive return on equity of 8.60%. Allergan’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the business posted $4.02 EPS.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Edgewood Management LLC increased its stake in Allergan by 2.6% during the 2nd quarter. Edgewood Management LLC now owns 5,728,391 shares of the company’s stock worth $955,037,000 after buying an additional 144,282 shares during the period. Janus Henderson Group PLC increased its position in shares of Allergan by 16.3% in the 2nd quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock valued at $796,712,000 after purchasing an additional 668,343 shares during the last quarter. Northern Trust Corp increased its position in shares of Allergan by 1.7% in the 2nd quarter. Northern Trust Corp now owns 4,163,556 shares of the company’s stock valued at $694,149,000 after purchasing an additional 69,651 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Allergan by 2.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,545,557 shares of the company’s stock valued at $591,116,000 after purchasing an additional 99,490 shares during the last quarter. Finally, Parnassus Investments CA increased its position in shares of Allergan by 3.1% in the 2nd quarter. Parnassus Investments CA now owns 1,844,804 shares of the company’s stock valued at $307,566,000 after purchasing an additional 55,029 shares during the last quarter. 77.48% of the stock is currently owned by hedge funds and other institutional investors.

In other Allergan news, Director Joseph H. Boccuzi bought 900 shares of the business’s stock in a transaction that occurred on Thursday, August 30th. The shares were purchased at an average cost of $190.59 per share, with a total value of $171,531.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christopher J. Coughlin bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 6th. The shares were acquired at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. 0.36% of the stock is owned by corporate insiders.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Featured Article: Understanding Average Daily Trade Volume

Earnings History and Estimates for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.